TRCT
SGP

Tower Research Capital (TRC)’s SpyGlass Pharma SGP Stock Holding History

Tower Research Capital (TRC)’s Portfolio SGP Stock Details SGP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.7K Buy
+750
New +$16.3K ﹤0.01% 3702

Other funds holding SGP

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Tower Research Capital (TRC)'s SGP Position: Q2 2026 in Review

Tower Research Capital (TRC) opened a new position in SpyGlass Pharma (SGP) in Q2 2026: 750 shares worth $16.7K. The stake represents ﹤0.01% of the portfolio and ranks #3702 among its holdings.

43 funds tracked by Wall St. Rank hold SGP as of Q2 2026.

  • Tower Research Capital (TRC) held 750 shares of SpyGlass Pharma worth $16.7K as of Q2 2026.
  • SpyGlass Pharma was a new Tower Research Capital (TRC) position in Q2 2026.
  • SpyGlass Pharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3702 holding.
  • 43 funds tracked by Wall St. Rank held SpyGlass Pharma as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.